AU2018283331B2 - Diazabicyclic substituted imidazopyrimidines and their use for the treatment of breathing disorders - Google Patents

Diazabicyclic substituted imidazopyrimidines and their use for the treatment of breathing disorders Download PDF

Info

Publication number
AU2018283331B2
AU2018283331B2 AU2018283331A AU2018283331A AU2018283331B2 AU 2018283331 B2 AU2018283331 B2 AU 2018283331B2 AU 2018283331 A AU2018283331 A AU 2018283331A AU 2018283331 A AU2018283331 A AU 2018283331A AU 2018283331 B2 AU2018283331 B2 AU 2018283331B2
Authority
AU
Australia
Prior art keywords
formula
methyl
diazabicyclo
imidazo
group
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
AU2018283331A
Other languages
English (en)
Other versions
AU2018283331A1 (en
Inventor
Udo Albus
Moritz Beck-Broichsitter
Karl COLLINS
Martina Delbeck
Doris Gehring
Michael Hahn
Niels Lindner
Klemens Lustig
Thomas Müller
Janine NICOLAI
Björn ROSENSTEIN
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Bayer AG
Bayer Pharma AG
Original Assignee
Bayer AG
Bayer Pharma AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bayer AG, Bayer Pharma AG filed Critical Bayer AG
Publication of AU2018283331A1 publication Critical patent/AU2018283331A1/en
Application granted granted Critical
Publication of AU2018283331B2 publication Critical patent/AU2018283331B2/en
Ceased legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4995Pyrazines or piperazines forming part of bridged ring systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D519/00Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/537Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines spiro-condensed or forming part of bridged ring systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/53751,4-Oxazines, e.g. morpholine
    • A61K31/53861,4-Oxazines, e.g. morpholine spiro-condensed or forming part of bridged ring systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D487/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04Ortho-condensed systems
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D487/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/08Bridged systems
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D498/00Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/08Bridged systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Pulmonology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
AU2018283331A 2017-06-14 2018-06-07 Diazabicyclic substituted imidazopyrimidines and their use for the treatment of breathing disorders Ceased AU2018283331B2 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
EP17176046 2017-06-14
EP17176046.5 2017-06-14
EP17193252 2017-09-26
EP17193252.8 2017-09-26
PCT/EP2018/064977 WO2018228907A1 (de) 2017-06-14 2018-06-07 Diazabicyclisch substituierte imidazopyrimidine und ihre verwendung zur behandlung von atemstörungen

Publications (2)

Publication Number Publication Date
AU2018283331A1 AU2018283331A1 (en) 2019-12-19
AU2018283331B2 true AU2018283331B2 (en) 2022-08-04

Family

ID=62492660

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2018283331A Ceased AU2018283331B2 (en) 2017-06-14 2018-06-07 Diazabicyclic substituted imidazopyrimidines and their use for the treatment of breathing disorders

Country Status (36)

Country Link
US (3) US11098063B2 (OSRAM)
EP (1) EP3638675B1 (OSRAM)
JP (2) JP6896113B2 (OSRAM)
KR (1) KR102364134B1 (OSRAM)
CN (4) CN110719911B (OSRAM)
AR (1) AR112099A1 (OSRAM)
AU (1) AU2018283331B2 (OSRAM)
BR (1) BR112019026450A2 (OSRAM)
CA (1) CA3066942A1 (OSRAM)
CL (1) CL2019003650A1 (OSRAM)
CO (1) CO2019014047A2 (OSRAM)
CR (1) CR20190563A (OSRAM)
CU (1) CU24603B1 (OSRAM)
DO (1) DOP2019000308A (OSRAM)
EA (1) EA202090043A1 (OSRAM)
EC (1) ECSP19088492A (OSRAM)
ES (1) ES2985167T3 (OSRAM)
GE (1) GEP20227366B (OSRAM)
HR (1) HRP20240678T1 (OSRAM)
HU (1) HUE066512T2 (OSRAM)
IL (1) IL271117B (OSRAM)
JO (1) JOP20190284A1 (OSRAM)
MA (1) MA49368B1 (OSRAM)
MX (2) MX2019014983A (OSRAM)
MY (1) MY204293A (OSRAM)
NI (1) NI201900126A (OSRAM)
NZ (1) NZ758821A (OSRAM)
PE (1) PE20200016A1 (OSRAM)
PH (1) PH12019502828A1 (OSRAM)
PL (1) PL3638675T3 (OSRAM)
RS (1) RS65543B1 (OSRAM)
SG (1) SG11201911508XA (OSRAM)
TW (1) TWI801388B (OSRAM)
UA (1) UA125186C2 (OSRAM)
UY (1) UY37773A (OSRAM)
WO (1) WO2018228907A1 (OSRAM)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2016365676A1 (en) 2015-12-10 2018-06-07 Bayer Pharma Aktiengesellschaft 2-phenyl-3-(piperazinomethyl)imidazo[1,2-a]pyridine derivatives as blockers of TASK-1 and TASK-2 channels, for the treatment of sleep-related breathing disorders
WO2018227427A1 (en) 2017-06-14 2018-12-20 Bayer Aktiengesellschaft Substituted bridged diazepane derivatives and use thereof
JOP20190284A1 (ar) 2017-06-14 2019-12-11 Bayer Pharma AG مركبات إيميدازوبيريميدين مستبدلة بديازا ثنائي الحلقة واستخدامها للمعالجة من اضطرابات التنفس
CA3139298A1 (en) 2019-05-09 2020-11-12 Bayer Aktiengesellschaft Combination of an a2-adrenoceptor subtype c (alpha-2c) antagonists with a task1/3 channel blocker for the treatment of sleep apnea
US20220218700A1 (en) * 2019-05-09 2022-07-14 Bayer Aktiengesellschaft Combination of an ?2-adrenoceptor subtype c (alpha-2c) antagonists with a task1/3 channel blocker for the treatment of sleep apnea
PE20221025A1 (es) 2019-11-06 2022-06-16 Bayer Ag Inhibidores de los receptores a2c adrenergicos
WO2022008426A1 (en) 2020-07-06 2022-01-13 Bayer Aktiengesellschaft Combination of an alpha2-adrenoceptor subtype c (alpha-2c) antagonist with a task1/3 channel blocker for the treatment of sleep apnea
GB202101734D0 (en) * 2021-02-08 2021-03-24 Cerevance Inc Novel Compounds
US20250057845A1 (en) 2021-12-22 2025-02-20 Bayer Aktiengesellschaft Combination of a task1/3 channel blocker with a p2x3 receptor antagonist for the treatment of sleep apnea
CA3259605A1 (en) 2021-12-22 2023-06-29 Bayer Aktiengesellschaft Combination of a task1/3 channel blocker with a norepinephrine reuptake inhibitor for the treatment of sleep apnea
EP4452246A1 (en) 2021-12-22 2024-10-30 Bayer Aktiengesellschaft Combination of a task1/3 channel blocker with a muscarinic receptor antagonist for the treatment of sleep apnea
US20250074899A1 (en) 2022-01-07 2025-03-06 Bayer Aktiengesellschaft A2-adrenoceptor subtype c antagonists for the treatment of sleep apnea
CA3248349A1 (en) 2022-01-07 2023-07-13 Bayer Aktiengesellschaft 2,3-DIHYDROBENZO[B][1,4]DIOXINE-2-YLMETHYL)PIPERAZINE-1-YL DERIVATIVES FOR THE TREATMENT OF SLEEP APNEA
AR133983A1 (es) 2023-09-28 2025-11-19 Bayer Ag Carboxamidas heterocíclicas sustituidas y su uso
CN117959293B (zh) * 2024-01-18 2025-05-13 香港大学深圳医院 非奈利酮在制备治疗和/或预防卵巢功能障碍疾病药物中的应用

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2013037914A1 (en) * 2011-09-16 2013-03-21 Sanofi Substituted 4,5,6,7-tetrahydro-1h-pyrazolo[4,3-c]pyridines, their use as medicament, and pharmaceutical preparations comprising them
WO2014187922A1 (en) * 2013-05-24 2014-11-27 Iomet Pharma Ltd. Slc2a transporter inhibitors
WO2016085783A1 (en) * 2014-11-26 2016-06-02 Merck Sharp & Dohme Corp. Bridged diazepane orexin receptor antagonists

Family Cites Families (48)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE19834044A1 (de) 1998-07-29 2000-02-03 Bayer Ag Neue substituierte Pyrazolderivate
DE19834047A1 (de) 1998-07-29 2000-02-03 Bayer Ag Substituierte Pyrazolderivate
DE19943639A1 (de) 1999-09-13 2001-03-15 Bayer Ag Dicarbonsäurederivate mit neuartigen pharmazeutischen Eigenschaften
DE19943634A1 (de) 1999-09-13 2001-04-12 Bayer Ag Neuartige Dicarbonsäurederivate mit pharmazeutischen Eigenschaften
DE19943635A1 (de) 1999-09-13 2001-03-15 Bayer Ag Neuartige Aminodicarbonsäurederivate mit pharmazeutischen Eigenschaften
DE19943636A1 (de) 1999-09-13 2001-03-15 Bayer Ag Neuartige Dicarbonsäurederivate mit pharmazeutischen Eigenschaften
MY125533A (en) 1999-12-06 2006-08-30 Bristol Myers Squibb Co Heterocyclic dihydropyrimidine compounds
WO2002002557A2 (en) 2000-06-30 2002-01-10 Neurogen Corporation 2-phenylimidazo[1,2-a]pyridine derivatives: a new class of gaba brain receptor ligands
GB0017256D0 (en) 2000-07-13 2000-08-30 Merck Sharp & Dohme Therapeutic agents
AR031176A1 (es) 2000-11-22 2003-09-10 Bayer Ag Nuevos derivados de pirazolpiridina sustituidos con piridina
SE0100568D0 (sv) 2001-02-20 2001-02-20 Astrazeneca Ab Compounds
DE10110750A1 (de) 2001-03-07 2002-09-12 Bayer Ag Neuartige Aminodicarbonsäurederivate mit pharmazeutischen Eigenschaften
DE10110749A1 (de) 2001-03-07 2002-09-12 Bayer Ag Substituierte Aminodicarbonsäurederivate
DE10220570A1 (de) 2002-05-08 2003-11-20 Bayer Ag Carbamat-substituierte Pyrazolopyridine
DE10247269A1 (de) 2002-10-10 2004-04-22 Grünenthal GmbH Substituierte C-Imidazo[1,2-a]pyridin-3-yl-methylamine
US7855194B2 (en) 2006-03-27 2010-12-21 Hoffmann-La Roche Inc. Pyrimidine, quinazoline, pteridine and triazine derivatives
NZ572231A (en) * 2006-04-27 2010-12-24 Sanofi Aventis Deutschland Inhibitors of the task-1 and task-3 ion channel
JP2009543785A (ja) * 2006-07-14 2009-12-10 メルク エンド カムパニー インコーポレーテッド 架橋ジアゼパンオレキシン受容体アンタゴニスト
EP1974729A1 (en) 2007-03-28 2008-10-01 Santhera Pharmaceuticals (Schweiz) AG Substituted imidazopyridine derivates as melanocortin- 4 receptor antagonists
WO2009143156A2 (en) 2008-05-19 2009-11-26 Sepracor Inc. IMIDAZO[1,2-a]PYRIDINE COMPOUNDS
US20130178475A1 (en) 2010-03-17 2013-07-11 Ironwood Pharmaceuticals, Inc. sGC STIMULATORS
AU2011229423B2 (en) 2010-03-18 2015-12-10 Institut National De La Sante Et De La Recherche Medicale (Inserm) Anti-infective compounds
DE102010021637A1 (de) 2010-05-26 2011-12-01 Bayer Schering Pharma Aktiengesellschaft Substituierte 5-Fluor-1H-Pyrazolopyridine und ihre Verwendung
JP6114189B2 (ja) 2010-07-09 2017-04-12 バイエル・インテレクチュアル・プロパティ・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツングBayer Intellectual Property GmbH 縮合ピリミジンおよびトリアジンならびに心血管障害の処置および/または予防のためのその使用
DE102010040233A1 (de) 2010-09-03 2012-03-08 Bayer Schering Pharma Aktiengesellschaft Bicyclische Aza-Heterocyclen und ihre Verwendung
DE102010043379A1 (de) 2010-11-04 2012-05-10 Bayer Schering Pharma Aktiengesellschaft Substituierte 6-Fluor-1H-Pyrazolo[4,3-b]pyridine und ihre Verwendung
US9000186B2 (en) 2011-02-01 2015-04-07 Kyowa Hakko Kirin Co., Ltd. Ring-fused heterocyclic derivative
US20140221354A1 (en) 2011-03-31 2014-08-07 Emblem Technology Transfer Gmbh IMIDAZO [1,2-a]PYRIDINE COMPOUNDS FOR USE IN THERAPY
KR20140093610A (ko) 2011-04-21 2014-07-28 재단법인 한국파스퇴르연구소 소염 화합물
MX2014002968A (es) 2011-09-12 2014-07-09 Sanofi Sa 4,5,6,7 - tetrahidro - 1h - pirazolo [4,3 -c] piridinas sustituidas con indanilo, su uso como medicamento, y preparaciones farmaceuticas que las comprenden.
EP2755973B1 (en) 2011-09-16 2015-11-04 Sanofi Substituted 4,5,6,7-tetrahydro-1h-pyrazolo[4,3-c]pyridines, their use as medicament, and pharmaceutical preparations comprising them
RU2650111C2 (ru) 2012-02-03 2018-04-09 Санофи Конденсированные пирролдикарбоксамиды и их применение в качестве фармацевтических средств
EA037928B1 (ru) 2014-03-26 2021-06-08 Ф. Хоффманн-Ля Рош Аг Бициклические соединения в качестве ингибиторов продукции аутотаксина (atx) и лизофосфатидиловой кислоты (lpa)
WO2016085784A1 (en) 2014-11-26 2016-06-02 Merck Sharp & Dohme Corp. Methyl diazepane orexin receptor antagonists
TWI585785B (zh) * 2014-11-26 2017-06-01 Murata Manufacturing Co Electronic parts manufacturing methods, electronic components and electronic devices
JP2018012645A (ja) 2014-11-26 2018-01-25 持田製薬株式会社 新規ジアザビシクロ誘導体
JP2018016544A (ja) 2014-12-03 2018-02-01 持田製薬株式会社 新規ジアザビシクロ[2.2.2]オクタン誘導体
AU2016328535A1 (en) 2015-09-24 2017-11-09 F. Hoffmann-La Roche Ag Bicyclic compounds as ATX inhibitors
JP2018538296A (ja) * 2015-12-10 2018-12-27 バイエル・ファルマ・アクティエンゲゼルシャフト 置換ペルヒドロピロロ[3,4−c]ピロール誘導体およびその使用
AU2016365676A1 (en) * 2015-12-10 2018-06-07 Bayer Pharma Aktiengesellschaft 2-phenyl-3-(piperazinomethyl)imidazo[1,2-a]pyridine derivatives as blockers of TASK-1 and TASK-2 channels, for the treatment of sleep-related breathing disorders
JOP20190005A1 (ar) 2016-07-20 2019-01-20 Bayer Ag مركبات ديازاهيترو ثنائية الحلقة مستبدلة واستخداماتها
JOP20190148A1 (ar) 2016-12-21 2019-06-18 Bayer Pharma AG أشكال جرعات صيدلية تحتوي على مثبطات قنوات task-1 و task-3 واستخدامها لمعالجة الاضطرابات التنفسية
JOP20190141A1 (ar) 2016-12-21 2019-06-12 Bayer Pharma AG أشكال جرعات صيدلية تحتوي على مثبطات لقناة task-1 و task-3 واستخدامها في معالجة اضطراب تنفسي
WO2018227427A1 (en) 2017-06-14 2018-12-20 Bayer Aktiengesellschaft Substituted bridged diazepane derivatives and use thereof
JOP20190284A1 (ar) 2017-06-14 2019-12-11 Bayer Pharma AG مركبات إيميدازوبيريميدين مستبدلة بديازا ثنائي الحلقة واستخدامها للمعالجة من اضطرابات التنفس
SG11202105551YA (en) 2018-11-27 2021-06-29 Bayer Ag Process for producing pharmaceutical dosage forms containing task-1 and task-3 channel inhibitors, and the use of same in breathing disorder therapy
US20220218700A1 (en) 2019-05-09 2022-07-14 Bayer Aktiengesellschaft Combination of an ?2-adrenoceptor subtype c (alpha-2c) antagonists with a task1/3 channel blocker for the treatment of sleep apnea
CA3139298A1 (en) 2019-05-09 2020-11-12 Bayer Aktiengesellschaft Combination of an a2-adrenoceptor subtype c (alpha-2c) antagonists with a task1/3 channel blocker for the treatment of sleep apnea

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2013037914A1 (en) * 2011-09-16 2013-03-21 Sanofi Substituted 4,5,6,7-tetrahydro-1h-pyrazolo[4,3-c]pyridines, their use as medicament, and pharmaceutical preparations comprising them
WO2014187922A1 (en) * 2013-05-24 2014-11-27 Iomet Pharma Ltd. Slc2a transporter inhibitors
WO2016085783A1 (en) * 2014-11-26 2016-06-02 Merck Sharp & Dohme Corp. Bridged diazepane orexin receptor antagonists

Also Published As

Publication number Publication date
EP3638675C0 (de) 2024-04-17
JOP20190284A1 (ar) 2019-12-11
KR102364134B1 (ko) 2022-02-18
CN110719911A (zh) 2020-01-21
CN115554300B (zh) 2024-10-29
KR20200014915A (ko) 2020-02-11
EP3638675B1 (de) 2024-04-17
AU2018283331A1 (en) 2019-12-19
ES2985167T3 (es) 2024-11-04
RS65543B1 (sr) 2024-06-28
BR112019026450A2 (pt) 2020-07-14
CN110719911B (zh) 2022-10-21
SG11201911508XA (en) 2020-01-30
MY204293A (en) 2024-08-21
US20250154175A1 (en) 2025-05-15
CN115554299A (zh) 2023-01-03
CA3066942A1 (en) 2018-12-20
MX2022012716A (es) 2022-11-07
DOP2019000308A (es) 2020-01-31
PL3638675T3 (pl) 2024-07-01
ECSP19088492A (es) 2019-12-27
MA49368A (fr) 2021-04-14
NI201900126A (es) 2020-04-02
US12180227B2 (en) 2024-12-31
CU24603B1 (es) 2022-06-06
CO2019014047A2 (es) 2020-01-17
JP6896113B2 (ja) 2021-06-30
PH12019502828A1 (en) 2020-10-26
CN115554300A (zh) 2023-01-03
EP3638675A1 (de) 2020-04-22
UY37773A (es) 2019-01-02
CR20190563A (es) 2020-04-22
CN115583959B (zh) 2024-04-26
CL2019003650A1 (es) 2020-07-10
US11098063B2 (en) 2021-08-24
JP2021127346A (ja) 2021-09-02
EA202090043A1 (ru) 2020-04-02
GEP20227366B (en) 2022-03-25
CN115583959A (zh) 2023-01-10
PE20200016A1 (es) 2020-01-06
NZ758821A (en) 2025-05-02
CU20190101A7 (es) 2020-10-20
JP2020523388A (ja) 2020-08-06
HRP20240678T1 (hr) 2024-08-16
US20220017540A1 (en) 2022-01-20
IL271117A (en) 2020-01-30
US20200109155A1 (en) 2020-04-09
WO2018228907A1 (de) 2018-12-20
MA49368B1 (fr) 2024-06-28
UA125186C2 (uk) 2022-01-26
TW201919638A (zh) 2019-06-01
MX2019014983A (es) 2020-02-24
HUE066512T2 (hu) 2024-08-28
IL271117B (en) 2022-03-01
AR112099A1 (es) 2019-09-18
TWI801388B (zh) 2023-05-11

Similar Documents

Publication Publication Date Title
AU2018283331B2 (en) Diazabicyclic substituted imidazopyrimidines and their use for the treatment of breathing disorders
US10414765B2 (en) Substituted perhydropyrrolo[3,4-c]pyrrole derivatives and the use of same
AU2017298421B2 (en) Substituted diazahetero-bicyclic compounds and their use
EP3638676B1 (en) Substituted bridged diazepane derivatives and use thereof as task-1 and task-3 inhibitors
HK40085266A (en) Diazabicyclic substituted imidazopyrimidines and their use for the treatment of breathing disorders
HK40085269A (en) Diazabicyclic substituted imidazopyrimidines and their use for the treatment of breathing disorders
HK40085267A (en) Diazabicyclic substituted imidazopyrimidines and their use for the treatment of breathing disorders
EA040559B1 (ru) Диазабициклические замещенные имидазопиримидины и их применение
HK40015098B (en) Diazabicyclic substituted imidazopyrimidines and their use for the treatment of breathing disorders
HK40015098A (en) Diazabicyclic substituted imidazopyrimidines and their use for the treatment of breathing disorders

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)